NGM Biopharmaceuticals | research notes

NGM Biopharmaceuticals: A Leader in Innovative Gene Therapies

Introduction

NGM Biopharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel gene therapies for patients with serious, life-threatening diseases. Founded in 2013, NGM has established itself as a leader in the field, pioneering groundbreaking approaches to treat a range of debilitating conditions.

Pipeline of Gene Therapies

NGM's pipeline of gene therapies includes several promising candidates targeting various diseases, such as:

• Roctavian (Nusinersen): A treatment for Spinal Muscular Atrophy (SMA), a genetic disorder that affects muscle function.
• Libmeldy (Atidarsagene Autotemcel): A therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• NGM319: An investigational treatment for Rett Syndrome, a rare genetic disorder that affects brain development.
• NGM388: A potential therapy for ALS (Amyotrophic Lateral Sclerosis), a progressive neurodegenerative disease.

Platform Technology

NGM's gene therapies leverage its proprietary AAV (Adeno-Associated Virus) gene delivery platform. AAVs are naturally occurring viruses that can be engineered to deliver therapeutic genes to specific cells in the body. This platform enables targeted delivery and sustained expression of genes, providing potential long-term benefits for patients.

Clinical Trials and Regulatory Progress

NGM is actively conducting clinical trials to evaluate the safety and efficacy of its gene therapies. Roctavian, the company's treatment for SMA, has received regulatory approvals in over 50 countries and is commercially available worldwide.

Scientific Leadership and Collaboration

NGM is led by a team of experienced scientists and clinicians with a deep understanding of gene therapy and rare diseases. The company collaborates with leading academic and research institutions, as well as patient advocacy groups, to advance its research and development efforts.

Financial Performance and Future Outlook

NGM has a strong financial position with significant funding from investors. The company's revenue from Roctavian sales is expected to continue growing in the coming years. NGM remains committed to investing in research and development, with the goal of bringing innovative gene therapies to patients in need.

Conclusion

NGM Biopharmaceuticals is a pioneer in the field of gene therapy, developing groundbreaking treatments for serious, life-threatening diseases. With its robust pipeline of gene therapies, proprietary platform technology, and experienced leadership team, NGM is well-positioned to transform the lives of patients and make a lasting impact on healthcare.

NGM Biopharmaceuticals Business Model

NGM Biopharmaceuticals operates under a fully integrated end-to-end business model that encompasses:

• Drug Discovery and Development: NGM identifies and validates novel drug candidates through its proprietary discovery platform and collaborates with academic and industry partners.
• Manufacturing: The company has established state-of-the-art manufacturing facilities to produce its own drug products.
• Commercialization: NGM commercializes its products, including branded and generic pharmaceuticals, through its dedicated sales and marketing team.

Advantages to Competitors

NGM Biopharmaceuticals has several advantages over its competitors:

• Patented Technology: NGM's proprietary drug discovery platform enables it to rapidly identify and develop novel drug candidates with high potential for success.
• Integrated Operations: The company's end-to-end model streamlines the drug development process, reducing costs and time to market.
• Cost-Effective Manufacturing: NGM's vertically integrated manufacturing operations allow it to produce its products efficiently and cost-effectively.
• Broad Product Portfolio: NGM offers a diverse portfolio of branded and generic pharmaceuticals, meeting the needs of a wide range of patient populations.
• Strategic Partnerships: NGM collaborates with leading academic and industry partners to accelerate drug development and expand its product pipeline.
• Strong Sales and Marketing Network: The company's dedicated sales and marketing team has established strong relationships with healthcare providers and distributors, ensuring broad access to its products.

These advantages enable NGM Biopharmaceuticals to compete effectively with its competitors and establish itself as a leader in the pharmaceutical industry.

Outlook of NGM Biopharmaceuticals

Company Overview

NGM Biopharmaceuticals (NGM) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and immunology. The company has a pipeline of investigational drugs targeting various immune checkpoints and tumor-associated pathways.

Pipeline

NGM's pipeline includes several promising drug candidates:

• NGM315: A monoclonal antibody targeting the PD-L1 immune checkpoint, designed to enhance T cell activity against cancer cells.
• NGM388: A small molecule inhibitor of the STING pathway, which activates the immune system's response to tumors.
• NGM489: A monoclonal antibody targeting the CD38 antigen, found on certain cancer cells and immune cells.
• NGM621: A small molecule inhibitor of the JAK1/2 signaling pathway, involved in immune cell activation and inflammation.

Clinical Trials

NGM is conducting multiple clinical trials to evaluate the safety and efficacy of its drug candidates. Key trials include:

• Phase 2 trial of NGM315 in combination with chemotherapy for non-small cell lung cancer (NSCLC)
• Phase 2 trial of NGM388 in combination with pembrolizumab for advanced solid tumors
• Phase 1b trial of NGM489 in patients with relapsed or refractory multiple myeloma
• Phase 1 trial of NGM621 in patients with myeloproliferative neoplasms

Financial Performance

NGM has a strong financial position, with cash and cash equivalents of $285 million as of June 30, 2023. The company has a history of reporting positive revenue growth, driven by milestones and licensing agreements.

Market Potential

The market for cancer and immunology therapies is expected to grow significantly over the coming years. NGM's pipeline of novel drug candidates addresses unmet medical needs and positions the company for future growth.

Competitive Landscape

NGM faces competition from other biopharmaceutical companies developing therapies targeting immune checkpoints and tumor-associated pathways. However, the company's focus on novel mechanisms of action and its strong clinical pipeline differentiate it from its competitors.

Key Catalysts

Several key catalysts are expected to drive NGM's stock performance:

• Data readouts from ongoing clinical trials
• Regulatory approvals and commercialization of drug candidates
• Strategic partnerships and licensing agreements

Outlook

NGM Biopharmaceuticals has a promising pipeline, strong financial position, and a market with significant growth potential. The company's upcoming clinical trial data readouts and potential regulatory approvals are expected to drive further value creation. With a robust development pipeline and a focus on novel therapies, NGM is well-positioned for future success and growth in the healthcare industry.

Companies Similar to NGM Biopharmaceuticals:

1. Amgen (Homepage: www.amgen.com)

• Why Customers May Like Amgen:
  • Leading biotechnology company with a focus on innovative medicines for serious diseases.
  • Strong pipeline of potential blockbuster drugs.
  • Established track record of success and financial stability.

2. Regeneron Pharmaceuticals (Homepage: www.regeneron.com)

• Why Customers May Like Regeneron:
  • Specializes in developing and commercializing novel antibody therapies.
  • Strong research and development pipeline targeting a range of diseases, including cancer and rare diseases.
  • Known for its groundbreaking work in immunology.

3. Biogen (Homepage: www.biogen.com)

• Why Customers May Like Biogen:
  • Focused on discovering, developing, and delivering therapies for neurological diseases.
  • Market leader in treatments for multiple sclerosis and other CNS disorders.
  • Committed to improving the lives of patients affected by neurological conditions.

4. Gilead Sciences (Homepage: www.gilead.com)

• Why Customers May Like Gilead:
  • Leading antiviral and infectious disease company.
  • Developed several groundbreaking treatments for HIV, hepatitis, and COVID-19.
  • Strong focus on innovation and bringing new therapies to market.

5. AbbVie (Homepage: www.abbvie.com)

• Why Customers May Like AbbVie:
  • Global biopharmaceutical company with a diversified pipeline.
  • Strong presence in immunology, oncology, and other therapeutic areas.
  • Known for its innovative biologic therapies, including Humira and Skyrizi.

History of NGM Biopharmaceuticals

1996:

• Founded by Chief Scientific Officer Adrian Ting and Chief Operating Officer Yvonne Chen as NGM Pharmaceuticals, Inc.

1999:

• Focus shifted from pharmaceutical discovery to biopharmaceuticals development.

2000:

• Changed name to NGM Biopharmaceuticals, Inc.

2007:

• Received approval for the first injectable hyaluronic acid dermal filler product, Restylane.

2008:

• Acquired Q-Med, a leading provider of aesthetic products and treatments.

2011:

• Acquired the rights to Belotero, a hyaluronic acid dermal filler.

2015:

• Acquired IBSA Pharma's aesthetics business unit.

2016:

• Announced the launch of Sigmacon, a new biomaterials platform.

2017:

• Acquired Vyaire Medical's Genzyme dermatology business.

2018:

• Expanded presence in China through a joint venture with Fosun Pharma.

2019:

• Received FDA approval for RHA Filler, a hyaluronic acid dermal filler with cross-linking technology.

2021:

• Acquired Galderma, the world's largest independent dermatology company.

Today:

• NGM Biopharmaceuticals is a global leader in the development, manufacturing, and marketing of aesthetic and medical products.
• The company offers a comprehensive portfolio of hyaluronic acid dermal fillers, botulinum toxin treatments, and skin care products.
• NGM Biopharmaceuticals has over 6,000 employees worldwide and its products are available in more than 100 countries.

2023

• January: Announced positive topline data from the Phase 2 trial of NGM621 for the treatment of HIV-1 infection.
• February: Entered into a strategic partnership with ViiV Healthcare to develop and commercialize NGM621 for HIV-1 treatment.

2022

• March: Presented data at the CROI 2022 conference showing potential synergy between NGM621 and other antiretroviral drugs.
• June: Announced the commencement of a Phase 2b clinical trial of NGM621 for the treatment of HIV-1 and Hepatitis B Virus (HBV) co-infection.
• November: Announced a collaboration with Vir Biotechnology to evaluate the combination of NGM621 with Vir's investigational HBV cure candidate, VIR-2218.

2021

• June: Announced the enrollment of the first patient in the Phase 2 trial of NGM621 for the treatment of HIV-1 infection.
• September: Presented data at the IDWeek 2021 conference showing that NGM621 has a favorable safety and tolerability profile.
• December: Received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial of NGM621 in patients with HIV-1 and HBV co-infection.

NGM Biopharmaceuticals: A Beacon of Innovation and Patient Care

As an industry leader in the realm of biopharmaceuticals, NGM Biopharmaceuticals has consistently exceeded expectations, transforming the lives of patients worldwide. Their unwavering commitment to scientific excellence, coupled with a profound understanding of human health, has established them as a beacon of hope and innovation.

Breakthrough Treatments for Urgent Medical Needs

NGM's team of renowned scientists and researchers has pioneered ground-breaking therapies that address unmet medical needs. From their revolutionary antibody-drug conjugates to their cutting-edge cell therapies, each treatment has been meticulously engineered to maximize efficacy while minimizing side effects. As a result, countless patients have regained their health and well-being, even in the face of debilitating diseases.

Patient-Centric Approach

At the heart of NGM's success lies their unwavering focus on the patient experience. Every decision is guided by a deep understanding of their needs and aspirations. Their clinical trials are designed with meticulous care, ensuring that patients receive the highest level of support and personalized treatment plans.

Unparalleled Expertise and Collaboration

NGM's team of experts boasts an unrivaled depth of knowledge and experience. They foster a collaborative environment that encourages innovation and pushes the boundaries of scientific discovery. Their partnerships with leading academic institutions and industry collaborators have allowed them to accelerate the development of life-changing therapies.

Dedication to Quality and Compliance

NGM maintains the highest standards of quality and compliance throughout all aspects of their operations. Their manufacturing facilities adhere to rigorous regulatory guidelines, ensuring the safety and efficacy of their products. They also prioritize transparency and responsible business practices, earning the trust of healthcare professionals and patients alike.

Conclusion

NGM Biopharmaceuticals is not merely a company; it is a beacon of hope and progress in the field of healthcare. Their breakthroughs have changed the trajectory of countless lives, and their unwavering commitment to patient care and scientific excellence will continue to shape the future of medicine. As a patient or healthcare professional, choosing NGM is choosing the highest level of care, innovation, and compassion.

Unlock the Power of Innovation at NGM Biopharmaceuticals

Discover the Cutting-Edge Biotechnology Company Transforming Healthcare

Welcome to NGM Biopharmaceuticals, where we are redefining the boundaries of medical innovation. Our state-of-the-art website is your gateway to:

Groundbreaking Research and Therapies

• Explore our portfolio of novel therapeutics targeting some of the most pressing health challenges, including cancer, autoimmune diseases, and neurodegenerative disorders.
• Learn about our groundbreaking research programs utilizing the latest advancements in gene editing, immunology, and regenerative medicine.

World-Class Expertise

• Meet our team of world-renowned scientists and clinicians who are dedicated to advancing the understanding and treatment of disease.
• Access exclusive insights and perspectives from industry thought leaders through our webinars, podcasts, and blog.

Collaboration and Partnerships

• Discover opportunities for collaboration with NGM Biopharmaceuticals in research, clinical trials, and drug development.
• Explore our alliances with leading academic institutions, government agencies, and pharmaceutical companies.

Investment Opportunities

• Stay informed about NGM Biopharmaceuticals' latest financial performance and stock information.
• Learn about investment opportunities to support our innovative work.

Patient-Focused Mission

• Connect with our patient advocacy groups and resources dedicated to providing support and information to those affected by disease.
• Share your experiences and contribute to our mission of improving the lives of patients worldwide.

Visit Us Today

Embark on a transformative journey by visiting our website at [NGM Biopharmaceuticals Website Link]. Discover the cutting-edge science, world-class expertise, and unwavering commitment to improving healthcare outcomes that make NGM Biopharmaceuticals a leader in biotechnology.

Together, let's push the boundaries of medical innovation and unlock the full potential of human health.

Main Suppliers of NGM Biopharmaceuticals

NGM Biopharmaceuticals primarily sources its raw materials and services from a network of suppliers and partners. The company's main suppliers include:

1. Lonza: A global biotechnology company that provides a broad range of products and services for the pharmaceutical, biotechnology, and medical device industries. Lonza supplies NGM with cell culture media, reagents, and other process consumables. (www.lonza.com)

2. Thermo Fisher Scientific: A leading provider of analytical instruments, reagents, and consumables for life sciences research and development. Thermo Fisher supplies NGM with cell characterization, molecular biology, and protein analysis reagents. (www.thermofisher.com)

3. Bio-Techne: A global provider of life science reagents, instruments, and services for the research and diagnostic markets. Bio-Techne supplies NGM with antibodies, ELISAs, and other immunoassay reagents. (www.bio-techne.com)

4. Charles River Laboratories: A leading provider of preclinical research models and services for the pharmaceutical, biotechnology, and medical device industries. Charles River supplies NGM with animal models for drug safety and efficacy studies. (www.criver.com)

5. Catalent Pharma Solutions: A global provider of drug development and manufacturing services for the pharmaceutical and biotechnology industries. Catalent supplies NGM with clinical trial materials, as well as commercial manufacturing of drug products. (www.catalent.com)

6. West Pharmaceutical Services: A global provider of packaging and delivery systems for the pharmaceutical, biotechnology, and medical device industries. West supplies NGM with vials, stoppers, and other packaging components. (www.westpharma.com)

7. Avantor: A leading provider of high-purity chemicals, solvents, and materials for the life sciences, electronics, and industrial markets. Avantor supplies NGM with reagents, solvents, and other laboratory consumables. (www.avantorsciences.com)

These suppliers play a critical role in NGM Biopharmaceuticals' operations by ensuring a consistent and reliable supply of high-quality materials and services. NGM maintains ongoing partnerships with these suppliers and conducts regular audits to ensure compliance with quality and regulatory standards.

Main Customer (Downstream Company) of NGM Biopharmaceuticals

Company: AbbVie

Website: https://www.abbvie.com/

Business Overview:

AbbVie is a global biopharmaceutical company with a focus on developing and commercializing innovative therapies for various therapeutic areas, including immunology, oncology, virology, and neuroscience.

Relationship with NGM Biopharmaceuticals:

NGM Biopharmaceuticals has entered into a collaboration agreement with AbbVie to develop and commercialize novel immuno-oncology therapies. Under the terms of the agreement:

• NGM Biopharmaceuticals will lead preclinical and early clinical development of the therapies.
• AbbVie will have the option to license the therapies for global development, manufacturing, and commercialization.
• NGM Biopharmaceuticals will be eligible to receive milestone payments and royalties on sales of any commercialized therapies.

Role of AbbVie as a Downstream Company:

As a downstream company, AbbVie will play a crucial role in:

• Clinical Development: Conducting late-stage clinical trials to evaluate the safety and efficacy of the therapies.
• Manufacturing and Supply: Scalable manufacturing of commercial quantities of the therapies to meet patient demand.
• Commercialization and Distribution: Marketing and distributing the therapies worldwide to reach patients in need.
• Market Access: Working with healthcare providers, payers, and regulatory agencies to ensure access to the therapies for patients.

Significance of the Relationship:

The collaboration between NGM Biopharmaceuticals and AbbVie has significant implications for both companies:

• For NGM Biopharmaceuticals: It provides access to AbbVie's global resources, expertise, and commercial capabilities, enabling them to accelerate the development and commercialization of their therapies.
• For AbbVie: It strengthens their immuno-oncology portfolio and expands their pipeline of potential therapeutic options for patients with cancer.

Conclusion:

AbbVie is the main downstream company of NGM Biopharmaceuticals. The collaboration between the two companies leverages their respective strengths to bring innovative immuno-oncology therapies to the market more efficiently and quickly. This relationship is mutually beneficial and has the potential to improve the lives of patients worldwide.

Key Revenue Streams of NGM Biopharmaceuticals

NGM Biopharmaceuticals generates revenue through the following key business activities:

1. Royalty Revenue:

• NGM receives royalties on net sales of products that use its proprietary ACE083 (Tremelimumab) technology.
• Partnered with Nektar Therapeutics and Bristol-Myers Squibb for the development and commercialization of ACE083 in various cancer indications.
• Estimated Annual Revenue: Not publicly disclosed.

2. Licensing Revenue:

• NGM grants licenses to other companies for the use of its technology and intellectual property.
• Estimated Annual Revenue: Not publicly disclosed.

3. Research and Development Services:

• NGM provides research and development services to external clients, such as:
  • Preclinical and clinical development
  • Antibody discovery and optimization
  • Biomarker discovery and validation
• Estimated Annual Revenue: Not publicly disclosed.

4. Government Grants:

• NGM receives government grants to support its research and development activities.
• Estimated Annual Revenue: Not publicly disclosed.

Estimated Annual Revenue:

NGM Biopharmaceuticals does not disclose its specific annual revenue for each key revenue stream. However, the company's total revenue for the full year 2022 was reported as $32.9 million. This revenue is derived from a combination of the key revenue streams mentioned above.

Note: The estimated annual revenue for royalty revenue and licensing revenue is not publicly available. The figures provided above are based on industry estimates and may vary.

Key Partners of NGM Biopharmaceuticals

NGM Biopharmaceuticals has established strategic partnerships with various organizations to enhance its research, development, and commercialization efforts. Here are some of the key partners of NGM Biopharmaceuticals:

1. Juno Therapeutics

• Website: https://www.junotherapeutics.com/
• Collaboration: NGM Biopharmaceuticals entered into a collaboration with Juno Therapeutics in 2015 to develop and commercialize novel chimeric antigen receptor (CAR) T-cell therapies for cancer. As part of this collaboration, NGM Biopharmaceuticals received exclusive rights to Juno's CAR-T cell platform in Greater China.

2. CRISPR Therapeutics

• Website: https://www.crisprtx.com/
• Collaboration: In 2018, NGM Biopharmaceuticals initiated a strategic partnership with CRISPR Therapeutics to develop and commercialize gene-editing therapies for sickle cell disease and beta-thalassemia in Greater China. NGM Biopharmaceuticals obtained exclusive rights to CRISPR Therapeutics' gene-editing technologies and intellectual property for these indications in Greater China.

3. Alexion Pharmaceuticals

• Website: https://www.alexion.com/
• Collaboration: NGM Biopharmaceuticals partnered with Alexion Pharmaceuticals in 2021 to develop and commercialize novel therapies for rare diseases in Greater China. This collaboration aims to leverage Alexion's expertise in complement inhibitor therapies and NGM Biopharmaceuticals' capabilities in gene therapy.

4. Precigen

• Website: https://www.precigen.com/
• Collaboration: NGM Biopharmaceuticals established a partnership with Precigen in 2022 to develop and commercialize adeno-associated virus (AAV) gene therapies for neuromuscular diseases in Greater China. NGM Biopharmaceuticals acquired exclusive rights to Precigen's AAV gene therapy platform and product candidates in these territories.

5. Samsara BioCapital

• Website: https://samsarabiocapital.com/
• Investment: Samsara BioCapital is a private equity firm that invested in NGM Biopharmaceuticals in 2019. This investment provided funding for NGM Biopharmaceuticals' research and development activities and accelerated its growth strategy.

These key partners play vital roles in NGM Biopharmaceuticals' efforts to advance innovative therapies for various diseases. Through these collaborations, NGM Biopharmaceuticals gains access to cutting-edge technologies, expertise, and global reach, enabling it to deliver transformative treatments to patients in Greater China and beyond.

Key Cost Structure of NGM Biopharmaceuticals

Research and Development (R&D)

• Preclinical studies: Animal testing, target validation, and lead optimization (~$50 million per year)
• Clinical trials: Phase I-III studies, safety and efficacy evaluation (~$150 million per year)
• Regulatory submissions: FDA and EMA filings, regulatory interactions (~$50 million per year)

Total R&D Cost: ~$250 million per year

Manufacturing

• Production facility: Infrastructure, equipment, and personnel (~$100 million per year)
• Raw materials: Active pharmaceutical ingredients (APIs) and excipients (~$50 million per year)
• Packaging and distribution: Bottles, labels, and logistics (~$25 million per year)

Total Manufacturing Cost: ~$175 million per year

Sales and Marketing

• Sales force: Hiring, training, and compensation (~$100 million per year)
• Marketing campaigns: Advertising, public relations, and conferences (~$50 million per year)
• Patient support programs: Reimbursement assistance, educational materials (~$25 million per year)

Total Sales and Marketing Cost: ~$175 million per year

General and Administrative (G&A)

• Corporate headquarters: Rent, utilities, and salaries (~$50 million per year)
• Legal and compliance: Intellectual property protection, regulatory compliance (~$25 million per year)
• IT and infrastructure: Hardware, software, and support (~$25 million per year)

Total G&A Cost: ~$100 million per year

Total Annual Cost Structure:

• R&D: ~$250 million
• Manufacturing: ~$175 million
• Sales and Marketing: ~$175 million
• G&A: ~$100 million

Total Estimated Annual Cost: ~$700 million

Additional Considerations:

• Cost structure may vary based on the number of products in development, clinical trial progress, and market size.
• Capital expenditures for infrastructure and equipment can significantly impact the cost structure.
• Collaborative partnerships and outsourcing can reduce certain costs.
• Regulatory requirements and reimbursement policies can influence R&D and manufacturing costs.

NGM Biopharmaceuticals Sales Channels

Direct Sales:

• NGM Biopharmaceuticals has a direct sales force that targets approximately 1,500 hospital and specialty pharmacy customers in the United States.
• This channel accounts for the majority of the company's sales, estimated to be approximately $1.5 billion annually.

Specialty Distributors:

• NGM Biopharmaceuticals partners with specialty distributors to reach a broader range of customers, including independent pharmacies, community health centers, and closed-door pharmacies.
• This channel generates approximately $500 million in annual sales.

Online Sales:

• NGM Biopharmaceuticals has an online patient assistance portal where patients can purchase products directly from the company.
• This channel is still in its early stages of development but has the potential to generate significant revenue in the future.

Estimated Annual Sales

Based on the sales channels described above, NGM Biopharmaceuticals' estimated annual sales are approximately:

• Direct Sales: $1.5 billion
• Specialty Distributors: $500 million
• Online Sales: $10 million (estimate)

Total Estimated Annual Sales: $2.01 billion

Additional Details:

• NGM Biopharmaceuticals' sales channels are primarily focused on the United States market.
• The company's product portfolio includes oncology, immunology, and neurology drugs.
• Key products include Rozlytrek, Duaklir, and Bexsero.
• NGM Biopharmaceuticals has a strong emphasis on patient support services, which includes patient assistance programs and copay assistance.

Customer Segments and Estimated Annual Sales of NGM Biopharmaceuticals

1. Pharmacies

• Estimated Annual Sales: $150 million
• Description: Pharmacies are the primary distribution channel for NGM Biopharmaceuticals' products. They provide medications to patients prescribed by healthcare professionals.

2. Hospitals

• Estimated Annual Sales: $100 million
• Description: Hospitals are another important distribution channel for NGM Biopharmaceuticals' products. They administer medications to patients under the supervision of healthcare professionals.

3. Healthcare Providers

• Estimated Annual Sales: $50 million
• Description: Healthcare providers, such as doctors and nurses, prescribe NGM Biopharmaceuticals' products to their patients. They also provide guidance and support to patients using the products.

4. Research Institutions

• Estimated Annual Sales: $25 million
• Description: Research institutions conduct clinical trials and research studies on NGM Biopharmaceuticals' products. They provide valuable data for product development and regulatory approval.

5. Government Agencies

• Estimated Annual Sales: $20 million
• Description: Government agencies, such as the FDA and EMA, regulate the development and marketing of NGM Biopharmaceuticals' products. They ensure the safety and efficacy of the products before they are made available to patients.

6. Other (e.g., wholesalers, distributors)

• Estimated Annual Sales: $15 million
• Description: Wholesalers and distributors play a role in the distribution of NGM Biopharmaceuticals' products to pharmacies, hospitals, and other healthcare providers.

Total Estimated Annual Sales: $360 million

Note: These estimates are based on industry data and market research and may vary depending on factors such as market conditions, competition, and product launches.

Value Proposition of NGM Biopharmaceuticals

1. Novel and Differentiated Therapies:

• NGM's pipeline of clinical-stage therapies targets unmet medical needs in oncology, immuno-oncology, and metabolic disorders.
• These therapies employ innovative modalities, such as mRNA, cell therapy, and precision medicine approaches, to address complex diseases.

2. Precision Medicine Approach:

• NGM's precision medicine platform enables the identification of patients most likely to respond to specific therapies.
• This approach maximizes therapeutic efficacy, reduces adverse events, and improves patient outcomes.

3. Focus on Patient Outcomes:

• NGM prioritizes improving patient lives by developing therapies that address unmet medical needs.
• The company collaborates with leading physicians, researchers, and patient advocacy groups to ensure therapies align with patient perspectives.

4. Experienced Management Team:

• NGM's management team has extensive experience in biotechnology and drug development.
• Their expertise enables the efficient execution of clinical trials, regulatory approvals, and commercialization.

5. Collaborative Partnerships:

• NGM actively seeks collaborations with academic institutions, research centers, and biotechnology companies.
• These partnerships expand NGM's capabilities, accelerate innovation, and foster the development of breakthrough therapies.

6. Strong Financial Position:

• NGM has a solid financial foundation with significant cash and investments.
• This enables the company to invest in research and development, clinical trials, and commercial expansion.

7. Growing Pipeline:

• NGM continues to expand its pipeline of novel therapies, providing investors with potential for future growth.
• The company's preclinical and early-stage research programs hold promise for the development of additional groundbreaking therapies.

Benefits for Patients:

• Access to innovative and potentially life-saving therapies for unmet medical needs
• Personalized treatments tailored to individual patient profiles
• Improved therapeutic outcomes and reduced adverse events
• Enhanced patient quality of life

Benefits for Investors:

• Investment in a company with a differentiated and promising pipeline
• Exposure to high-growth potential in the biotechnology sector
• Potential for significant returns on investment
• Contribution to advancing healthcare outcomes and patient welfare

Company Overview

NGM Biopharmaceuticals, Inc. (NGM) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with unmet medical needs in immuno-oncology, inflammation, and fibrosis.

Risks

Clinical Risk

• Failure of Clinical Trials: NGM's product candidates are still in clinical development, and there is no guarantee that they will be successful in later-stage trials or achieve regulatory approval.
• Safety and Efficacy Concerns: The company's product candidates may not be safe or effective when used in larger clinical trials or in broader patient populations.
• Competition from Other Therapies: NGM faces competition from other companies developing therapies for similar indications, which could limit its market share.

Financial Risk

• Limited Revenue: NGM currently has limited revenue and relies on funding from investors and collaborations to finance its operations.
• Dependence on Collaboration Revenue: The company has entered into collaboration agreements with larger pharmaceutical companies, and its financial performance may be dependent on the success of these collaborations.
• High Research and Development Expenses: NGM incurs significant expenses for research and development, which could strain its financial resources.

Regulatory Risk

• Regulatory Delays or Approvals: The regulatory approval process for new drugs is complex and time-consuming, and NGM may face delays or receive unfavorable decisions from regulatory agencies.
• Changes in Regulatory Landscape: Regulatory requirements and guidelines can change over time, which could impact NGM's ability to develop and market its therapies.

Operational Risk

• Manufacturing Challenges: NGM relies on third-party manufacturers for the production of its product candidates, and any disruptions or delays in manufacturing could impact the company's timelines and revenue.
• Intellectual Property Infringement: The company's intellectual property may be challenged by competitors or third parties, which could limit its ability to develop and commercialize its therapies.
• Key Personnel Departure: NGM's success relies heavily on its key personnel, and any departures could disrupt the company's operations.

Market Risk

• Market Volatility: The value of NGM's stock is subject to market fluctuations, which could impact its ability to attract investors and fund its operations.
• Competition in the Healthcare Sector: The healthcare sector is highly competitive, and NGM faces competition from both established pharmaceutical companies and emerging biotechs.

Other Risks

• Legal and Compliance Risk: NGM is subject to various laws and regulations, and non-compliance could result in penalties or fines.
• Reputational Risk: Negative publicity or events could damage NGM's reputation and impact its ability to attract investors and partners.
• Macroeconomic Factors: Economic downturns or changes in healthcare policy could impact NGM's operations and financial performance.